{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:50:44Z","timestamp":1774356644469,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07687-0","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:03:28Z","timestamp":1768579408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MCM8 promotes colorectal cancer progression by competitively inhibiting HRD1-mediated CDC42 ubiquitination and degradation"],"prefix":"10.1186","volume":"24","author":[{"given":"Siyi","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longwu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"7687_CR1","doi-asserted-by":"publisher","first-page":"1208140","DOI":"10.3389\/fonc.2023.1208140","volume":"13","author":"S Tirendi","year":"2023","unstructured":"Tirendi S, Marengo B, Domenicotti C, et al. Colorectal cancer and therapy response: a focus on the main mechanisms involved. Front Oncol. 2023;13:1208140.","journal-title":"Front Oncol"},{"key":"7687_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/CIA.S109285","volume":"11","author":"K Simon","year":"2016","unstructured":"Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967\u201376.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"7687_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"YH Xie","year":"2020","unstructured":"Xie YH, Chen YX, Fang J Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.","journal-title":"Signal Transduct Target Ther"},{"key":"7687_CR4","doi-asserted-by":"crossref","unstructured":"Tamraz M, Ghossaini AL, Temraz N, S. Optimization of colorectal cancer screening strategies: new insights. World J Gastroenterol. 2024;30(28):3361\u201366.","DOI":"10.3748\/wjg.v30.i28.3361"},{"issue":"10","key":"7687_CR5","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3748\/wjg.v29.i10.1569","volume":"29","author":"W Leowattana","year":"2023","unstructured":"Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023;29(10):1569\u201388.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"7687_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","volume":"44","author":"AE Shin","year":"2023","unstructured":"Shin AE, Giancotti FG, Rustgi A K. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44(4):222\u201336.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"7687_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ejmech.2004.12.006","volume":"40","author":"PS Ludwig","year":"2005","unstructured":"Ludwig PS, Schwendener RA, Schott H. Synthesis and anticancer activities of amphiphilic 5-fluoro-2\u2019-deoxyuridylic acid prodrugs. Eur J Med Chem. 2005;40(5):494\u2013504. https:\/\/doi.org\/10.1016\/j.ejmech.2004.12.006.","journal-title":"Eur J Med Chem"},{"key":"7687_CR8","doi-asserted-by":"publisher","first-page":"111285","DOI":"10.1016\/j.biopha.2021.111285","volume":"137","author":"C Sethy","year":"2021","unstructured":"Sethy C, Kundu CN. 5-fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137:111285. https:\/\/doi.org\/10.1016\/j.biopha.2021.111285.","journal-title":"Biomed Pharmacother"},{"key":"7687_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dnarep.2019.02.003","volume":"76","author":"WC Griffin","year":"2019","unstructured":"Griffin WC, Trakselis MA. The MCM8\/9 complex: a recent recruit to the roster of helicases involved in genome maintenance. DNA Repair (Amst). 2019, Apr;76:1\u201310.","journal-title":"DNA Repair (Amst)"},{"issue":"8","key":"7687_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1128\/MCB.01503-12","volume":"33","author":"J Park","year":"2013","unstructured":"Park J, Long DT, Lee KY, Abbas T, Shibata E, Negishi M, et al. The MCM8-MCM9 complex promotes RAD51 recruitment at DNA damage sites to facilitate homologous recombination. Mol Cell Biol. 2013, Apr;33(8):1632\u201344.","journal-title":"Mol Cell Biol"},{"key":"7687_CR11","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.1038\/ncomms8744","volume":"6","author":"KY Lee","year":"2015","unstructured":"Lee KY, Im JS, Shibata E, Park J, Handa N, Kowalczykowski SC, Dutta A. C. Nat Commun. 2015, Jul, 28;6:7744.","journal-title":"Nat Commun"},{"issue":"4","key":"7687_CR12","first-page":"e 1165","volume":"8","author":"YX Zhang","year":"2020","unstructured":"Zhang YX, He WB, Xiao WJ, Meng LL, Tan C, Du J, et al. Novel loss-of-function mutation in MCM8 causes premature ovarian insufficiency. Mol Genet Evidence Med. 2020, Apr;8(4):e 1165.","journal-title":"Mol Genet Evidence Med"},{"issue":"4","key":"7687_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41419-021-03621-y","volume":"12","author":"Z Ren","year":"2021","unstructured":"Ren Z, Li J, Zhao S, Qiao Q, Li R. Knockdown of MCM8 functions as a strategy to inhibit the development and progression of osteosarcoma through regulating CTGF. Cell Death Dis. 2021, Apr, 7;12(4):376.","journal-title":"Cell Death Dis"},{"issue":"27","key":"7687_CR14","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1038\/s41388-021-01888-1","volume":"40","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang L, Song Y, Jiang Y, Zhang D, Wang R, et al. MCM8 is regulated by EGFR signaling and promotes the growth of glioma stem cells through its interaction with DNA-replication-initiating factors. Oncogene. 2021, Jul;40(27):4615\u201324.","journal-title":"Oncogene"},{"issue":"2","key":"7687_CR15","first-page":"576","volume":"102","author":"S Desai","year":"2017","unstructured":"Desai S, Wood-Trageser M, Matic J, Chipkin J, Jiang H, Bachelot A, et al. MCM8 and MCM9 nucleotide variants in women with primary ovarian insufficiency. J Clin Endocrinol Metab. 2017, Feb, 1;102(2):576\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"7687_CR16","doi-asserted-by":"publisher","first-page":"e0164150","DOI":"10.1371\/journal.pone.0164150","volume":"11","author":"YP Peng","year":"2016","unstructured":"Peng YP, Zhu Y, Yin LD, Zhang JJ, Guo S, Fu Y, et al. The expression and prognostic roles of MCMs in Pancreatic cancer. PLoS One. 2016, Oct, 3;11(10):e0164150.","journal-title":"PLoS One"},{"key":"7687_CR17","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"C Narayanans","year":"2020","unstructured":"Narayanans C, Assarafyg, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.","journal-title":"Drug Resist Updat"},{"issue":"11","key":"7687_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43(11):1144\u201361.","journal-title":"Arch Pharm Res"},{"key":"7687_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3389\/fphar.2018.01080","volume":"9","author":"T Yuan","year":"2018","unstructured":"Yuan T, Yan F, Ying M, et al. Inhibition of ubiquitin-specific proteases as a Novel anticancer therapeutic strategy. Front Pharmacol. 2018;9:1080.","journal-title":"Front Pharmacol"},{"issue":"7","key":"7687_CR20","first-page":"485","volume":"19","author":"W Gielsdorf","year":"1981","unstructured":"Gielsdorf W, Schubert K. Biotransformation of doxylamine: isolation, identification and synthesis of some metabolites (author\u2019s transl). J Clin Chem Clin Biochem. 1981;19(7):485\u201390.","journal-title":"J Clin Chem Clin Biochem"},{"key":"7687_CR21","first-page":"101","volume":"2020","author":"L Arpalahti","year":"1233","unstructured":"Arpalahti L, Haglund C, Holmberg C I. Proteostasis dysregulation in Pancreatic cancer. Adv Exp Med Biol. 1233;2020:101\u201315.","journal-title":"Adv Exp Med Biol"},{"key":"7687_CR22","doi-asserted-by":"publisher","first-page":"102423","DOI":"10.1016\/j.jaut.2020.102423","volume":"109","author":"Y Xu","year":"2020","unstructured":"Xu Y, Fang D. Endoplasmic reticulum-associated degradation and beyond: the multitasking roles for HRD1 in immune regulation and autoimmunity. J Autoimmun. 2020;109:102423.","journal-title":"J Autoimmun"},{"issue":"3","key":"7687_CR23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1042\/BST20210112","volume":"49","author":"NP Murphy","year":"2021","unstructured":"Murphy NP, Mott HR, Owen D. Progress in the therapeutic inhibition of Cdc42 signalling. Biochem Soc Trans. 2021;49(3):1443\u201356.","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"7687_CR24","doi-asserted-by":"publisher","first-page":"e37317","DOI":"10.1371\/journal.pone.0037317","volume":"7","author":"KR Stengel","year":"2012","unstructured":"Stengel KR, Zheng Y. Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting. PLoS One. 2012;7(6):e37317.","journal-title":"PLoS One"},{"issue":"8","key":"7687_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cac2.12459","volume":"43","author":"X Hu","year":"2023","unstructured":"Hu X, Ma Z, Xu B, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun (Lond). 2023;43(8):909\u201337.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"7687_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40164-022-00344-4","volume":"11","author":"T Wang","year":"2022","unstructured":"Wang T, Rao D, Yu C, et al. RHO GTPase family in hepatocellular carcinoma. Exp Hematol Oncol. 2022;11(1):91.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"7687_CR27","doi-asserted-by":"publisher","first-page":"13071513","DOI":"10.3390\/cancers13071513","volume":"13","author":"CW Fhu","year":"2021","unstructured":"Fhu CW, Ali A. Dysregulation of the ubiquitin proteasome System in human malignancies: a window for therapeutic intervention. Cancers (Basel). 2021;13(7):13071513.","journal-title":"Cancers (basel)"},{"issue":"19","key":"7687_CR28","doi-asserted-by":"publisher","first-page":"27196515","DOI":"10.3390\/molecules27196515","volume":"27","author":"J Lee","year":"2022","unstructured":"Lee J, Lee Y, Jung Y M, et al. Discovery of E3 ligase ligands for target protein degradation. Molecules. 2022;27(19):27196515.","journal-title":"Molecules"},{"issue":"1","key":"7687_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","volume":"9","author":"Q Li","year":"2024","unstructured":"Li Q, Geng S, Luo H, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):266.","journal-title":"Signal Transduct Target Ther"},{"key":"7687_CR30","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"7687_CR31","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15. A pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u201367.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"7687_CR32","doi-asserted-by":"publisher","first-page":"106737","DOI":"10.1016\/j.isci.2023.106737","volume":"26","author":"NC Helderman","year":"2023","unstructured":"Helderman NC, Terlouw D, Bonjoch L, et al. Molecular functions of MCM8 and MCM9 and their associated pathologies. iScience. 2023;26(6):106737.","journal-title":"iScience"},{"issue":"24","key":"7687_CR33","doi-asserted-by":"publisher","first-page":"14415","DOI":"10.1111\/jcmm.16062","volume":"24","author":"B Huang","year":"2020","unstructured":"Huang B, Lin M, Lu L, et al. Identification of mini-chromosome maintenance 8 as a potential prognostic marker and its effects on proliferation and apoptosis in gastric cancer. J Cell Mol Med. 2020;24(24):14415\u201325.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"7687_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-021-01948-2","volume":"21","author":"W Zhu","year":"2021","unstructured":"Zhu W, Gao F, Zhou H, et al. Knockdown of MCM8 inhibits development and progression of bladder cancer in vitro and in vivo. Cancer Cell Int. 2021;21(1):242.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"7687_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/s12967-023-04084-9","volume":"21","author":"S Yu","year":"2023","unstructured":"Yu S, Dai W, Zhao S, et al. Function and mechanism of MCM8 in the development and progression of colorectal cancer. J Transl Med. 2023;21(1):623.","journal-title":"J Transl Med"},{"issue":"18","key":"7687_CR36","doi-asserted-by":"publisher","first-page":"e140698","DOI":"10.1172\/jci.insight.140698","volume":"5","author":"M Golubicki","year":"2020","unstructured":"Golubicki M, Bonjoch L, Acu\u00f1a-Ochoa JG, et al. Germline biallelic Mcm8 variants are associated with early-onset Lynch-like syndrome. JCI Insight. 2020;5(18):e140698. https:\/\/doi.org\/10.1172\/jci.insight.140698. Published 2020 Sep 17.","journal-title":"JCI Insight"},{"issue":"3","key":"7687_CR37","doi-asserted-by":"publisher","first-page":"e24267","DOI":"10.1002\/jcla.24267","volume":"36","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Jin D, Mou X, et al. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis. J Clin Lab Anal. 2022;36(3):e24267.","journal-title":"J Clin Lab Anal"},{"issue":"10","key":"7687_CR38","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1093\/brain\/awad184","volume":"146","author":"M Zhu","year":"2023","unstructured":"Zhu M, Xiao B, Xue T, et al. Cdc42GAP deficiency contributes to the Alzheimer\u2019s disease phenotype. Brain. 2023;146(10):4350\u201365.","journal-title":"Brain"},{"issue":"2","key":"7687_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41419-023-05648-9","volume":"14","author":"W Xie","year":"2023","unstructured":"Xie W, Han Z, Zuo Z, et al. ASAP1 activates the IQGAP1\/CDC42 pathway to promote tumor progression and chemotherapy resistance in gastric cancer. Cell Death Dis. 2023;14(2):124.","journal-title":"Cell Death Dis"},{"issue":"6","key":"7687_CR40","doi-asserted-by":"publisher","first-page":"12061521","DOI":"10.3390\/cancers12061521","volume":"12","author":"CM Novak","year":"2020","unstructured":"Novak CM, Horst EN, Lin E, et al. Compressive stimulation enhances ovarian cancer proliferation, invasion, chemoresistance, and mechanotransduction via CDC42 in a 3D bioreactor. Cancers (Basel). 2020;12(6):12061521.","journal-title":"Cancers (basel)"},{"key":"7687_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fcell.2020.00201","volume":"8","author":"M Maldonado M D","year":"2020","unstructured":"Maldonado MDM, Medina JI, Velazquez L, et al. Targeting Rac and Cdc42 GEFs in metastatic cancer. Front Cell Dev Biol. 2020;8:201.","journal-title":"Front Cell Dev Biol"},{"key":"7687_CR42","doi-asserted-by":"crossref","unstructured":"Xia J, Xu M, Hu H, et al. 5, 7, 4\u2019-trimethoxyflavone triggers cancer cell PD-L1 ubiquitin-proteasome degradation and facilitates antitumor immunity by targeting HRD1 (2020). Med Comm. 2024;5(7):e611.","DOI":"10.1002\/mco2.611"},{"issue":"Pt A","key":"7687_CR43","doi-asserted-by":"publisher","first-page":"113107","DOI":"10.1016\/j.intimp.2024.113107","volume":"142","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang F, Fan Y, Qiu C, Wang K. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway. Int Immunopharmacol. 2024;142(Pt A):113107. https:\/\/doi.org\/10.1016\/j.intimp.2024.113107.","journal-title":"Int Immunopharmacol"},{"key":"7687_CR44","first-page":"230","volume-title":"Front Biosci","author":"L Wang","year":"2023","unstructured":"Wang L, Liu X. Pan-cancer multi-Omics analysis of Minichromosome maintenance proteins (MCMs) expression in human Cancers. In: Front Biosci. Landmark. 2023;28(9):230.","edition":"Landmark"},{"issue":"10","key":"7687_CR45","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1172\/JCI37694","volume":"119","author":"M Maillet","year":"2009","unstructured":"Maillet M, Lynch J M, Sanna B, et al. Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest. 2009;119(10):3079\u201388.","journal-title":"J Clin Invest"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07687-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:53:20Z","timestamp":1774353200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7687"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07687-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7116246\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Hunan Cancer Hospital of Central South University. (Certificate number: 2025\u2013357*). All patients provided their informed written consent to participate in this study. All experiments on mice were conducted in accordance with the guidelines approved by the Experimental Animal Welfare and Ethics Committee of Central South University (Certificate number: APU-2025\u20130166).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agree on the publication of the results of the present manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}